SUPPLEMENTARY MATERIAL

Supplementary Table 1. Description of levels and attributes.

Levels	Attribute 1: IGF-I level control	Treatment correspondence
1	IGF-I levels control in 9 out of 10 patients	Pegvisomant
2	IGF-I levels control in 6 out of 10 patients	Octreotide/Lanreotide
3	IGF-I level control in 3 out of 10 patients	Pasireotide
Levels	**Attribute 2: Tumour control**	
1	Reduces tumour size	Octreotide/Lanreotide/Pasireotide
2	Does not reduce tumour size	Pegvisomant
Levels	**Attribute 3: Administration methods**	
1	Daily self-administered injection at home	Pegvisomant
2	Monthly self-administered or nurse-administered injection in primary care/hospital	Lanreotide
3	Monthly nurse-administered injection in primary care/hospital	Octreotide/Pasireotide
Levels	**Attribute 4: Pain associated to the administration method**	
1	Minimal injection pain and no redness/ bruising/ skin hardening	All treatments may cause pain or redness/bruises of the skin
2	Minimal injection pain but may cause redness/ bruising/ skin hardening	
3	Injection may be painful and cause redness/ bruising/ skin hardening	
Levels	**Attribute 5: Adverse events: diarrhoea**	
1	Diarrhoea in 1 out of 10 patients	Pegvisomant
2	Diarrhoea in 3 out of 10 patients	Pasireotide
3	Diarrhoea in 4 out of 10 patients	Lanreotide/Octreotide
Levels	**Attribute 6: Blood sugar levels control in blood**	
1	Improved blood sugar (or diabetes), or blood sugar medication down-dosed	Pegvisomant
2	Blood sugar (or diabetes) or blood sugar medication unaffected	Octreotide/Lanreotide
3	Blood sugar higher (or diabetes onset), or blood sugar medication may be required/up-dosed	Pasireotide
Levels	**Attribute 7: Storage conditions**	
1	Storage at room temperature	Pegvisomant
2	Cold storage (fridge)	Lanreotide/Octreotide/Pasireotide
Levels	**Attribute 8: Quality of life**	
1	Improves quality of life	All treatments may improve the QoL
2	Does not improve quality of life	

IGF-I levels 1,2 and 3 correspond to the efficacy reported for pegvisomant, lanreotide/octreotide and pasireotide, respectively. Level 1 of Tumour control correspond to the SSA analogues and level 2 to

pegvisomant. Level 1, 2 and 3 of the administration methods' attribute correspond to pegvisomant, lanreotide and octreotide/pasireotide, respectively. Diarrhoea attribute's level 1, 2 and 3 correspond to pegvisomant, pasireotide and lanreotide/octreotide, respectively. Attribute 4 and 8 do not correspond to any treatment

Figure S1: Subgroup analysis of utility level of attributes and levels, depending on years on treatment



Figure S2: Subgroup analysis of utility level of attributes and levels, depending on diabetes diagnosis



Arrows represent the absolute difference between the improvement of blood sugar levels or diabetes, or decrease of the medication and the rise in the levels or the need of medication.

Figure S3: Subgroup analysis of utility level of attributes and levels, depending on current line of treatment



Figure S4: Modification of preference share between hypothetical treatments differing just for the level of one or two attributes.